Lesson plan

NMNAT3

Nicotinamide mononucleotide adenylyltransferase 3 (NMNAT3) is an enzyme that in humans is encoded by the NMNAT3 gene. NMNAT3 is the third of three protein isoforms of nicotinamide-nucleotide adenylyltransferase (NMNAT) found in humans. As with the other NMNATs, NMNAT3 is an enzyme that catalyzes nicotinamide adenine dinucleotide (NAD) synthesis. NMNAT3 levels are highest in liver, heart, skeletal muscle, and erythrocytes. NMNAT3 is localized in mitochondria or cytoplasm, depending upon the cell type. Knockdown of NMNAT3 gene expression in cell culture strongly reduces mitochondrial function. NMNAT3 is essential for maintaining NAD in red blood cells. The catechin epigallocatechin gallate found in tea can activate NMNAT3 by more than 40%. Until January 2026, mutations in the NMNAT3 gene had not been associated with any known human disease, although it had been discovered that NMNAT3 deficiency causes hemolytic anemia in mice. In January 2026, researchers at the University Medical Center Utrecht in Utrecht, The Netherlands, were the first to link NMNAT3 deficiency to disease in vivo, in a patient with unexplained hereditary hemolytic anemia. The patient was successfully treated by supplementing NAD.

Back to article

Article summary

Nicotinamide mononucleotide adenylyltransferase 3 (NMNAT3) is an enzyme that in humans is encoded by the NMNAT3 gene. NMNAT3 is the third of three protein isoforms of nicotinamide-nucleotide adenylyltransferase (NMNAT) found in humans. As with the other NMNATs, NMNAT3 is an enzyme that catalyzes nicotinamide adenine dinucleotide (NAD) synthesis. NMNAT3 levels are highest in liver, heart, skeletal muscle, and erythrocytes. NMNAT3 is localized in mitochondria or cytoplasm, depending upon the cell type. Knockdown of NMNAT3 gene expression in cell culture strongly reduces mitochondrial function. NMNAT3 is essential for maintaining NAD in red blood cells. The catechin epigallocatechin gallate found in tea can activate NMNAT3 by more than 40%. Until January 2026, mutations in the NMNAT3 gene had not been associated with any known human disease, although it had been discovered that NMNAT3 deficiency causes hemolytic anemia in mice. In January 2026, researchers at the University Medical Center Utrecht in Utrecht, The Netherlands, were the first to link NMNAT3 deficiency to disease in vivo, in a patient with unexplained hereditary hemolytic anemia. The patient was successfully treated by supplementing NAD.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.